Rainbow Seed Fund News

Cambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody™ VH therapeutics, today announced the appointment of Dr Barbara Fleck as Head of Intellectual Property. Barbara Fleck, a European and Chartered Patent Attorney, has over 13 years’ experience of Intellectual Property issues in the bio therapeutics field, including […]

read more

Antibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus Cambridge, UK: 17 November 2015 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody™ VH therapeutics, today announced the appointment of Dr. Kevin Johnson as non-executive Chairman of the Board of Directors. The appointment is effective immediately. Dr. Johnson brings […]

read more

Read the thoughts of Chris Martin Non Executive Directors on the Rainbow Seed Advisory board in the Financial Times.  

read more

1 2 3